Market Data 
Markets
Replies to post #2245 on Cannabis Investment Club
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. The Science
Board to the Food and Drug
Administration will consider challenges
in evaluating the safety of dietary
supplement and food ingredients with
predicted pharmacological activity,
utilizing cannabinoids as a case study.
Other ingredients used in supplements and food available in the US also could be on the agency's radar for generating pharmacological activity.
Those ingredients include:
kratom, a botanical marketed for its calming and anti-inflammatory benefits;
the amino acid N-acetyl-L-cysteine used to increase glutathione levels and support respiratory health and detoxification in the liver and kidney;
and numerous analogs of pharmaceutical stimulants used in non-compliant weight loss and sports training supplements.
Cannabinoids, though, are the focus of this Science Board discussion. And for good reason.
Options for Congress
Congress could choose to maintain the federal prohibition on marijuana, but if it wanted to address the Schedule I status, it could do a number of things: (1) amend the CSA to move marijuana to a less restrictive schedule; (2) create an entirely new schedule or other category for marijuana; or (3) remove it
entirely from the CSA. If marijuana remains a controlled substance under the CSA under any schedule, that would maintain the existing conflict between the federal government and states that have legalized recreational marijuana, though moving marijuana to a less restrictive schedule could help mitigate conflicts between federal law and state medical marijuana laws. The creation of a new schedule solely for marijuana would give Congress an opportunity to modify the criminality of marijuana under the CSA. If Congress chose to remove marijuana from the CSA entirely, it could seek to regulate and tax commercial marijuana activities.
AI
